Ladies and gentlemen, thank you for standing by. Welcome to Royalty Pharma's Second Quarter 2025 Earnings Conference Call. I would like now to turn the conference over to George Grofik, Senior Vice President, Head of Investor Relations and Communications. Please go ahead, sir. Good morning and good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's second quarter 2025 results. You can find the press release with our earnings results and slides to this call on the Investors page of our website at royaltypharma.com. Moving to Slide 3. I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from these statements. We refer you to our most recent 10-K on file with the SEC for a description of these risks. All forward-looking statements are based on information currently available to Royalty Pharma, and we assume no obligation to update any such forward-looking statements. Non-GAAP liquidity measures will be used to help you understand our financial results, and the reconciliation of these measures to our GAAP financials is provided in the earnings press release available on our website. And with that, please advance to Slide 4. Our speakers on the call today are Pablo Legorreta, Founder and Chief Executive Officer; Marshall Urist, EVP, Head of Research and Investments; and Terry Coyne, EVP, Chief Financial Officer. Pablo will discuss the key highlights, after which Marshall will provide a portfolio update and Terry will review the financials. Following concluding remarks from Pablo, we will hold a Q&A session in which we will also be joined by Chris Hite, EVP, Vice Chairman. And with that, I'd like to turn the call over to Pablo.

Thank you, George, and welcome to everyone on the call. I am delighted to report a successful quarter of execution against our vision to be the leading partner funding innovation in life sciences. Slide 6 summarizes our strong business momentum in the second quarter. In terms of the financials, we delivered 20% growth in Portfolio Receipts, our top line to $727 million, an 11% growth in Royalty Receipts to $672 million. This was ahead of the guidance we provided last quarter for Portfolio Receipts of $700 million to $725 million due to the strength of our diversified portfolio. Turning to capital allocation. We purchased another 8 million shares in the second quarter, taking our total share repurchase this year to $1 billion. At the same time, in the second quarter, we deployed capital of just under $600 million on value-creating royalty transactions. Looking at our portfolio, we completed the acquisition of our external manager, which combines our leading royalty portfolio with our valuable investment platform to become an integrated company, an important milestone in our evolution. In addition, we announced a groundbreaking collaboration with Revolution Medicines, which we believe represents a new funding paradigm for innovative biotech companies. Under this agreement, we will provide up to $2 billion of flexible funding anchored by a synthetic royalty on the exciting Phase III oncology therapy, daraxonrasib. We also received encouraging clinical news on several portfolio therapies, including positive Phase III results for Gilead's Trodelvy in first-line metastatic triple-negative breast cancer. Lastly, we are pleased to raise our full year 2025 top line guidance. We now expect Portfolio Receipts to be between $3.05 billion and $3.15 billion, which represents growth of around 9% to 12%. We're also improving our guidance for full year operating and professional costs to a range of 9% to 9.5% of Portfolio Receipts compared with around 10% previously. This reflects immediate cost savings from our internalization transaction. Third, we'll provide further guidance on the significant savings in operating and professional costs for the remainder of the year and beyond. Consistent with our standard practice, our guidance is based on our current portfolio and does not include the benefit of any future transactions. Slide 7 shows our consistent track record of average double-digit growth since our IPO. As I noted earlier, we delivered 11% growth in Royalty Receipts in the second quarter. This takes us to 11% growth in the first half of 2025, which supports our confidence in delivering our updated full year guidance. I would also highlight that we have delivered this impressive track record of consistent growth, irrespective of the economic and financial markets backdrop. This really demonstrates our ability to execute successfully and consistently against our strategy in the growing market for biopharma royalties. With that, I will hand it over to Marshall.

Thanks, Pablo. I want to focus today on our innovative partnership with Revolution Medicines. Slide 9 gives a high-level view of our deal. We will provide up to $2 billion in long-term funding that will help the company aggressively pursue clinical development and commercialization of its practice-changing therapy daraxonrasib for RAS-mutant pancreatic and lung cancers. Of this amount, $1.25 billion is comprised of synthetic royalty funding, including $250 million we've already paid upfront. The remaining $750 million is senior secured debt that becomes available over time, beginning with FDA approval. Royalty Pharma expects to generate an internal rate of return in the teens, with peak potential annual royalties in excess of $170 million. We and the market see daraxonrasib as a multi-blockbuster based on stellar Phase I efficacy, and we anticipate the first Phase III readout in second-line metastatic pancreatic cancer in 2026. At a broader level, we think this will serve as a blueprint for a new funding approach that allows the most innovative biopharma companies to access large-scale capital while keeping full control of pipeline development and global commercialization and retaining full strategic optionality, thus capturing more value for shareholders. Pablo used the term groundbreaking to describe this partnership, and it's indeed getting a lot of attention across the industry. Now let's turn to Slide 10 to take a closer look at the detail. What's really powerful about this agreement is both the scale and the flexibility. It is a true win-win for both Revolution Medicines and Royalty Pharma. The royalty structure on daraxonrasib provides an attractive risk-reward for both of us, with additional funding becoming available upon clinical and regulatory progress as well as sales thresholds. Importantly, for our partner, most of this additional funding is optional and comes at a successively lower cost of capital. On top of that, we'll receive royalties on a second pipeline therapy, zoldonrasib, once it is approved in an overlapping indication. The daraxonrasib consensus model shows over $7 billion in worldwide sales by 2035, which translates to as much as $170 million in peak annual royalties to Royalty Pharma. The full details of this transaction are shown in the appendix of this presentation. The credit facility further scales the capital available to Revolution Medicines. It's tranche-based on achievement of product approvals and sales thresholds, so it grows as the company grows. We have the flexibility to syndicate some or all of this 6-year loan with other investors. Slide 11 gets to the core of why there is so much excitement surrounding daraxonrasib. The unmet need in pancreatic cancer is profound. According to the American Cancer Society, the 5-year survival is just 13%, and it's now the third leading cause of cancer-related deaths in the U.S. The opportunity is substantial with around 56,000 new pancreatic cancer patients diagnosed each year. And for most, chemotherapy is the only option. Assuming success in Phase III, Revolution Medicines would have a significant first-to-market advantage. We see a similar dynamic in non-small cell lung cancer, where chemotherapy is the only option for second-line treatment for most patients. Here, Revolution Medicines is currently enrolling a Phase III study in the second and third-line setting with primary completion expected by the end of 2027. As I also noted, if development in other RAS-driven tumors succeeds, we also benefit. To summarize, we think daraxonrasib can transform care for RAS-mutant cancers, especially in metastatic pancreatic cancer where patients desperately need new options. It's a high-impact program with significant commercial potential, and we are proud to be a part of it. With that, I'll hand it over to Terry.

Thanks, Marshall. Let's move to Slide 13. This slide shows how our efficient business model generates substantial cash flow to be reinvested. As you heard from Pablo, Royalty Receipts grew by 11% in the second quarter, reflecting the strength of our diversified portfolio. The key drivers were the strong performances of Voranigo, Trelegy, Evrysdi, and Tremfya. In addition, we benefited from a one-time payment of approximately $50 million in milestones and other contractual receipts, which was anticipated within our prior guidance. This resulted in Portfolio Receipts, our top line of $727 million, which was growth of 20%. As we move down the column, operating professional costs equated to 12.9% of Portfolio Receipts. This included approximately $35 million of one-time expense related to the internalization transaction. Excluding this item, the ratio would have been just over 8% of Portfolio Receipts, within our historical range. Net interest was a small positive of $8 million in the quarter, reflecting the semiannual timing of our interest payment schedule with payments primarily in the first and third quarters and the interest we received for the cash on our balance sheet. Moving further down the column, we have consistently stated that when we think of the cash generated by the business to then be redeployed into value-enhancing royalties, we look to portfolio cash flow, which is adjusted EBITDA less net interest paid. This amounted to $641 million in the quarter, equivalent to a margin of around 88%. This reflects a high underlying level of cash conversion and once again underscores the efficiency of our business model. Capital deployment in the quarter was $595 million. This primarily included the $250 million upfront for Revolution Medicines, a $200 million manufacturing milestone payment related to Adstiladrin, and R&D funding for litifilimab. Lastly, our weighted average share count declined by 35 million shares, largely as a result of our share buyback program. Slide 14 provides more detail on the evolution of our top line in the second quarter. Royalty Receipts, which we consider our recurring cash inflows, grew by 11%, helped by the strength of our diversified portfolio, which I highlighted earlier. I would also note that one of the drivers this quarter was Voranigo, which was $26 million in Royalty Receipts after being launched by Servier only last August. We are excited to see the profound impact it is having for glioma patients as it quickly becomes one of our top royalties and is on track to rapidly become a blockbuster. Portfolio Receipts, which grew by 20% in the quarter, benefited from the one-time payment that I described earlier and is slightly ahead of the range we guided to for the quarter. This takes our top line growth for the first six months to 18%, and supports our confidence in delivering another strong year of growth. Slide 15 shows that we continue to maintain significant financial capacity to execute our strategy. In total, we have access to approximately $3.4 billion through a combination of cash on our balance sheet, the cash our business generates, and access to the debt markets. At the end of the second quarter, we had cash and equivalents of $632 million. In terms of our borrowing position, we have investment-grade debt outstanding of $8.2 billion. Our leverage now stands at around 3x total debt to EBITDA or 2.7x on a net basis. We also have undrawn financial capacity from our $1.8 billion revolver. Lastly, as you heard earlier, under our dynamic capital allocation framework, we continue to take advantage of the fundamental disconnect in our share price and repurchased shares in the quarter, taking our total repurchase activity to $1 billion for the first six months. We also grew our dividend and continued to deploy capital on attractive royalty deals. In total, we returned $1.26 billion to shareholders in the first six months, a record for Royalty Pharma. On Slide 16, we are raising our full year 2025 financial guidance. We now expect Portfolio Receipts to be in the range of $3.05 billion to $3.15 billion. Let me walk you through our assumptions. Starting with Portfolio Receipts, we are expecting growth of around 9% to 12%, up from 6% to 12% previously based on the strong momentum of our diversified portfolio. This takes into account the recent launch of Promacta generics as well as a range of scenarios for the launch of the Alyftrek and the impact of Medicare Part D redesign. Importantly, and consistent with our standard practice, this guidance is based on our portfolio as of today and does not take into account the benefit of any future royalty acquisitions. Turning to operating costs. Payments for operating and professional costs are now expected to be approximately 9% to 9.5% of Portfolio Receipts in 2025, down from 10% in our previous guidance. Keep in mind that in the first half of this year, operating and professional costs were greater than 12% of Portfolio Receipts, driven by the one-time expenses related to the internalization and the sale of the MorphoSys Development Funding Bonds. Collectively, these items are expected to impact full year costs by approximately $70 million or a little more than 2% of Portfolio Receipts. We expect operating and professional costs to be between 5% to 6% in the second half of the year as we begin to realize the full benefits of the internalization. Interest paid in 2025 is now expected to be around $275 million, with around $126 million to be paid in the third quarter and $8 million in the fourth quarter. This guidance includes the additional quarterly interest expense for the debt assumed as part of the internalization, but does not take into account interest received on our cash balance, which was $21 million in the first half. In summary, we have delivered a strong second quarter and first half, which puts us on track to deliver another full year of excellent financial performance in 2025 as reflected in our raised guidance. Now before I hand it over to Pablo, I should also note that we did not receive from Vertex the full royalty to which we are entitled on Alyftrek, specifically the royalty related to deuterated ivacaftor. As we have previously stated, we believe we are entitled to a royalty of 8% on sales of Alyftrek. However, Vertex only paid us a royalty of 4%. As a result, we commenced the dispute resolution process contemplated by the agreements relating to our royalties on Vertex's cystic fibrosis products. That process is subject to confidentiality obligations, and so we do not expect to provide any updates until the matter is resolved, which we anticipate by around the end of 2026. We continue to receive our full royalties on Trikafta, Kalydeco, Symdeko, and Orkambi. And with that, I would like to hand the call back to Pablo.

Thanks, Terry. To conclude, I am delighted with our strong performance so far in 2025. We have again delivered double-digit growth, and we've entered into a groundbreaking partnership and acquired a royalty on one of the most exciting oncology assets in clinical development. On top of this, we significantly increased the return of capital to our shareholders, and we're now an integrated company with all the benefits that it brings to our shareholders and our people. On Slide 18, I want to highlight an important event in partnership with MIT that took place in the second quarter and reflects our role in advancing the health care ecosystem. In June, we sponsored our fifth annual Accelerating Bio-Innovation Conference. The aim of this 3-day conference is to facilitate discussions on translational science and drug development and to connect diverse parties in the biopharma ecosystem. This year, we had a tremendous turnout of nearly 350 life sciences executives, including 127 CEOs, 79 scientists, and 4 Nobel laureates. The audience was balanced between industry, academia, and investment professionals. As with our previous conferences, the feedback we received was hugely positive and sets Royalty Pharma up well for future dialogue with many of the leading innovators in biopharma. This is another example of our win-win approach, and keeps us front of mind for those seeking a partner to fund their innovation. On my final slide, I want to remind you of our coming Investor Day on September 11. We have an exciting agenda, which will provide you with a comprehensive deep dive into our plans to drive shareholder value creation in the large and growing market for funding biopharma innovation. We think it's a truly unique and compelling story, and we hope you can join us. With that, we would be happy to take your questions.

We will now open up the call to your questions. Operator, please take the first question.

The first question comes from Chris Schott with JPMorgan.

I just had 2 here. Maybe first, coming back to the Revolution Medicines deal. I'm just interested in your capacity to do these types of deals. I know it's a smaller initial upfront, but could be a sizable amount of capital with obviously very attractive returns if it all works out. So should we think about this as kind of more like one-off type of transactions? Or could we think about Royalty doing kind of a wider range of these kinds of end-to-end structures like this? My second question was on China innovation and how Royalty is thinking about this. It seems like we're seeing a larger and larger percent of the industry, at least early-stage pipeline coming from China. How do you think about this from a Royalty perspective? So specifically, do these companies have the same royalty opportunities you've seen with maybe more traditional U.S. or European biotechs? And as a company, do you have the resources to diligence and develop relationships with some of these emerging companies?

Chris, thank you for your excellent questions. I'm going to take the first one, and I'll ask Marshall to take the second one. So with respect to the Revolution Medicines transaction, it's incredibly exciting for us. And as we shared with investors when we closed the deal in our press release, we believe this is groundbreaking. It's a new paradigm for us, for the industry, for biotech, exciting biotech companies seeking funding because it really puts Royalty Pharma as a very viable alternative to a big pharma partnership where companies typically give up a very significant portion of the economics. It could be 50-50 shared economics with a big pharma partner. Often, big pharma also takes a much larger share of the ex-U.S. economics because they have worldwide distribution. When they're discussing transactions with biotechs, they present that as an advantage they have. Also, what happens in these big pharma partnerships is that you now have a partner that will have opinions that may not coincide with the opinions of the biotech management, and it becomes complicated. So what's interesting about this is that we provided funding at scale up to $2 billion for this very exciting product and this great company with a fantastic management team that creates a win-win partnership. But to more precisely, just to touch on one of your questions: Can we do more of this? Absolutely, we can. We're actually having active discussions with many other potential partners. Obviously, when something like this happens, people notice that they could be another Revolution Medicines. We do have the capacity to analyze these deals and negotiate them, and we're very excited about this. I don't see this as a one-off. Obviously, transactions take time, and for us to agree on terms with partners requires a lot of things that have to fall in place. But I do expect that we will see more of this in the coming years. Royalty Pharma is extremely well positioned to do this based on our scale, cost of capital, and also knowledge. One very last thing I'll mention is that we've invested a lot of money over the last 5, 6, 7 years into data. One of the things we’re doing is acquiring data that we use to analyze our investments, along with having a data analytics team that has great people that we've gathered to use it for our own benefit, but also to share that with our partners. And again, this differentiates Royalty Pharma from other capital providers. So I'll turn it now over to Marshall to answer your second question.

Chris, thanks for the question on China. So no, it's a great question, and it probably won't surprise you to hear that something we've been focused on for a while now. I think we are really excited to see the new product development and the globalization of biopharma innovation. What's happening in China is exciting, and we are definitely focused on it helping us to grow the Royalty Pharma business. I think it's a great example of how our open and flexible business model allows us to shift focus on innovation wherever it happens around the world. A couple of points to make: We're excited to see this as a new source of both royalty creation and new royalties for us to potentially invest in the future. Also, there will definitely be opportunities over time to work directly with companies there like you're seeing us do here in the U.S. and Europe. We're definitely excited about that. Like I said, we've been focused on it for a while, and we're already actively engaged in developing relationships and potential investments there. So it's a place you'll continue to see focus from us in terms of new opportunities and something that we're excited about as part of our business in the future.

And the next question will come from Terence Flynn with Morgan Stanley.

Congrats on all the progress. I had 2. The first is, there's been a growing focus on the bladder cancer market given a number of innovative drugs that have been launched and are launching. I know you guys have some exposure there with Adstiladrin royalties. Just wondering if you can disclose what that royalty is tracking at on a dollar basis right now? And then maybe how you see the non-muscle invasive segment evolving just given some upcoming competitors that might be entering? And then the second one was just on the operating expenses. Is the 5% to 6% range that you talked about, Terry, for the second half of '25, is that the run rate we should think about for '26? And then how are you thinking about additional share repurchases from here?

Thanks for the question. So Terry, why don't you take this question about operating expenses, and then Marshall can talk about bladder cancer.

Sure. We're starting to see the benefits of internalization in our operating margin, with 5% to 6% of Portfolio Receipts going towards expenses in the second half of this year. We haven't provided guidance for next year yet, but we believe this trend is strong and moving in the direction we anticipated. When we completed the transaction, we projected reaching 4% to 5% of Portfolio Receipts, and we're on track for that, which makes us optimistic. Regarding share repurchases, it's going to be quite dynamic. We're excited about the opportunities ahead, as demonstrated by the Revolution Medicines deal. Our focus is on finding the right balance and using our capital allocation framework as a guide, considering the appeal of royalty deals and how our share price compares to its intrinsic value. We feel positive about the current status of our pipeline, which contributes to our enthusiasm.

Terence, regarding your second question about Adstiladrin, we have not revealed the nominal royalties associated with it, but I can share some insights on our perspective of the market and its potential growth. We are thrilled to be involved with Adstiladrin, and Ferring has made significant strides in developing this market, which has lacked innovation for quite some time. They are effectively launching and expanding this market. Our enthusiasm for Adstiladrin is based on a few key factors. First, it is the first to market and offers a compelling combination of efficacy, safety, and convenience for patients, making it an exciting offering. When we decided to invest, we recognized that other products would enter the market, but we view that positively, as it indicates growing interest in this area. We anticipate that patients will benefit from a variety of treatment options, and it’s definitely not a zero-sum situation. We are eager to see how the non-muscle invasive breast cancer market evolves going forward.

And the next question will come from Jason Gerberry with Bank of America.

Maybe one more on the RevMed deal. Curious how important to the upfront deal consideration was frontline PDAC? How do you view derisking of darax combinations with chemo specifically in the frontline PDAC setting? Or is that kind of more factored into the sort of the downstream optionality when you consider that? And then maybe just when we think about 2025 Portfolio Receipts guidance, can you identify what is the single biggest variable in that 3% delta?

Sure. So Marshall, why don't you take the Revolution Medicines question? And then, Terry, you can take the second question.

Sure. Jason, on the Revolution Medicines deal, I want to reiterate how excited we are both about this product and what it means for patients and how innovative this deal is. On the first-line question, we're really excited about the first-line opportunity, and I think certainly, the patient need there is just as great. We are excited to see Revolution Medicines develop it there. I won't go into a lot of detail on that except to say, yes, that's something we are excited about beyond second line. Also, just as a reminder, one of the tranches of the synthetic royalty deal is based on positive Phase III data in pancreatic cancer, so it's something that was contemplated as part of our deal.

And then, Jason, on your guidance question, we always try to look at a range of scenarios when providing our guidance. Some of the factors I mentioned before include the Promacta generics, Part D redesign, and FX. We try to stress test all of the potential sales scenarios for many of our products when doing that. That's how we came up with that range.

And the next question will come from Umer Raffat with Evercore.

I have several today, if that's okay. Maybe just step by step. First, Terry, you mentioned the change in how Vertex is putting out the royalties now. I also see consensus tracking at about $900 million in royalty payments to Royalty Pharma for the foreseeable future, the next several years. I guess how would you recommend we think through that while you guys are in the arbitration process? Secondly, maybe this is for Pablo and Marshall. Obviously, congrats on the RevMed deal and very intriguing structure of the deal around pancreatic data, pancreatic approval, etc. But there's one thing I can't seem to figure out, which is why were no tranches pegged to the Phase III lung cancer readout? And who decided that? Was it RevMed that decided that? Or was it Royalty Pharma? And then finally, on Spinraza durability, Biogen is obviously really emphasizing and so is Ionis, the salanersen program, which is the once-annual version of Spinraza. It prompted me to sort of go back and see how you guys structured the transaction. At least based on what was put out there, it looks like it was specifically focused on nusinersen, which is Spinraza. Would you guys have to buy into that? Just trying to think about how to think about the Spinraza franchise durability, if I may.

Umer, thanks for the question and good to hear you. Terry, or maybe Marshall can take the RevMed question, including the Phase III lung cancer point and talk about Spinraza. Then Terry can come back to Vertex.

Sure, Umer. On the first part of your question on the tranches and why they were tied to pancreatic cancer, I wouldn't read anything into that about our views on lung cancer. We are certainly excited about that. The tranches and the triggers and the timing were part of an extensive and collaborative discussion we had with RevMed about fitting the capital and the cadence of the capital coming in to fit their needs as they're thinking about their broader development program. So that was really the trigger. I think it's a good insight into how we develop these deals and these structures with our partners.

On CF, just to clarify, we see $850 million in 2026, declining to $750 million by 2030. During the arbitration process, what we know right now is that we're getting a 4% royalty. That’s what we know today. As this plays out, we’ll just have to wait and see. Right now, it's a 4% royalty. We believe strongly that we are entitled to an 8% royalty, but we need to let this process play out.

Terry, maybe you should point out the guidance you gave of $850 million going to $750 million or $700 million is based on what assumption in terms of the royalty rates.

That's based on consensus estimates.

Based on what royalty rate?

It's a low royalty rate.

And the next question will come from Mike Nedelcovych with TD Cowen.

I have 3. One is actually a follow-up on the Vertex dispute. In terms of timing, is end of 2026 the worst-case scenario? Is it within the realm of possibility, for example, that this dispute is settled much earlier than that? Or are there structural reasons why the arbitration absolutely must extend into 2026? That's my first question. My second question is on aficamten. Bristol's Camzyos has been performing much better of late, and I wonder how you interpret those trends. Do you view them as positive for the market opportunity as a whole and likely to accrue to aficamten's benefit as well? Or do you think it might make the competitor more difficult to dislodge? Either way, in what ways do you think aficamten might differentiate in the marketplace? My last question is actually on the ABI conference. It's very interesting. I'm curious if you might share with us one new thing that you learned at the conference about the industry that perhaps you have not heard in other venues.

Sure. Regarding the timing estimate we gave for the resolution of the Vertex dispute, it's a conservative time based on a lot of data on how much time it takes for a dispute to get resolved. Obviously, there are scenarios where this could get resolved much quicker. But we wanted to give you what actually happens in this kind of situation, and that's why we guided conservatively. Marshall can touch on the aficamten question.

Okay. Great. Mike, so first of all, just to confirm on Umer's last question: the next-generation Spinraza is included as part of our deal. So no concerns there on Spinraza sustainability because it is included. On Camzyos, we have been happy to see the uptake, and I think it confirms our view of the market and the unmet need there and the size of that market. I think it sets the stage for the aficamten launch nicely. So that's our view overall. Having options in a market for physicians and for patients is always a powerful thing. Some of the ease-of-use factors with aficamten will certainly be viewed positively by physicians. The data that Cytokinetics is developing around the product will be supportive, like you saw with the beta blocker comparison study that read out positively earlier this year. We remain really excited about aficamten, and the success of Camzyos only confirms that for us.

And the next question is going to come from Ash Verma with UBS.

I wanted to ask about just broadly on the biopharma royalty universe. I saw the transaction between HealthCare Royalty Partners and KKR. Just curious to get your thoughts on how competition scaling up impacts your ability to compete for new royalties, especially for large transactions?

Ash, thank you for the question. It's not a surprise to us. We've known HealthCare Royalty for probably 2 decades, know the team well, and it's not a surprise to us that they have been acquired by KKR. We expected that. Competition has been out in the market for decades. We know how to operate with competitors. There have been other things that have happened recently; there was another fund that was raised of $1 billion. A few things to remind you of: Royalty Pharma has a very different structure than the rest of the competitors we have. We're a fully integrated company with a very low cost of capital, a WACC of around 7%, and a cost of debt that is extremely low, just north of 3%. Our overall cost of debt is around 3%. To raise new debt will be slightly higher given the interest rates today. Our debt has a weighted average duration of 13 years. Royalty Pharma gives us access to the biggest capital markets in the world, where we can fund our business incredibly competitively; it's really a cost of capital equivalent to big pharma. This puts us in a very unique position. Scale is another critical factor. We're doing deals that are multibillion dollars sometimes as an upfront. We've invested $2 billion in Evrysdi with PTC. In the past, we got a royalty on Tysabri for $2 billion, a royalty in cystic fibrosis for close to $4 billion when you look at those 2 combined transactions. Our transactions with Revolution Medicines show that we can work with partners on large-scale deals. Many of our competitors' entire fund is the size of one of the transactions we do. They need to do transactions that are much smaller. The team at Royalty Pharma is probably the largest investment team in life sciences, working cohesively with a strong culture over decades. We feel confident about how Royalty Pharma is evolving and continues to evolve to stay ahead of the competition. We welcome competition as it provides viable alternatives for companies seeking funding. We tend to win when we find an asset because of our advantages: low cost of capital, scale, and our long-term relationships. I'll stop there. Thank you for the question.

And the next question will come from Geoff Meacham with Citi.

I wanted to get an updated view on policy and impact. I think when you look at what ultimately could impact net pricing and then also consensus assumptions, it's MFN and perhaps PBM reform, and we may get that by year-end. To what degree have you guys been proactive here to maybe assess the range of the impact? The second question, also another one on competition in the space. Does Royalty still see high interest in larger scale deals, i.e., like more than $1 billion? This is where you guys are the most differentiated. How would you rank synthetic deals as a strategic priority in this context? I think it used to be in the other top, but I wanted to kind of get an update there.

Yes, of course. Just quickly on competition. We believe there will continue to be very large transactions in our space, $1 billion plus. There are fewer of those larger transactions than those in the $250 million, $500 million range, which we have many of each year. What's interesting is that 10 years ago, it was rare to have a transaction of that size, and now it seems like every year we have transactions of that size. Voranigo was around $900 million plus. Tremfya was over $1 billion, Trelegy was $1.3 billion, and then the transactions with PTC that added up to about $2.1 billion. I am confident that this will continue. When I see the royalties being created, there are high single-digit low double-digit royalties for multibillion-dollar products. These royalties could be worth $1 billion plus and, in some cases, multiple billions. Regarding our China strategy, we have been working on it for some time, and we think it will start to pay off. The licensing deals from Chinese companies with Western companies will create high-value royalties that will also contribute to our portfolio. I think that’s an exciting new source of investment for us. Marshall will take the question on policy.

Geoff, yes, thanks for the question on MFN and policy impact in general. We are trying to stay close to developments with our advisers and consultants on policy in D.C. to think about various scenarios and what might happen. We have been taking a scenario-based approach to consider a wide range of scenarios as we look at new investments. This kind of environment highlights the advantages of our flexible model, allowing us to focus on investments that are most attractive while being able to respond to policy changes in real-time. We continue to watch this closely.

I show no further questions at this time. I would like to turn the call back over to Pablo for closing remarks.

Thank you, operator, and thank you to everyone on the call for your continued interest in Royalty Pharma. If you have any follow-up questions, please feel free to reach out to George Grofik and his team. Thank you very much.

This concludes today's conference call, and thank you for participating. You may now disconnect.